Chronic allograft nephropathy: Expression and localization of PAI-1 and PPAR-γ

Nephrology Dialysis Transplantation

Volumn 20, Issue 12, 2005, Pages 2812-2819

  Revelo, Monica P ^a   Federspiel, C Charles ^a   Helderman, Harold ^a   Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chronic allograft nephropathy; Macrophage; Peroxisome proliferator activated receptor ; Plasminogen activator inhibitor 1

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; AGED; ARTERIOSCLEROSIS; ARTICLE; CAUCASIAN; CHILD; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FEMALE; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHRECTOMY; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCORING SYSTEM; SEX RATIO; VASCULAR FIBROSIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MICROSCOPY, ELECTRON; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PPAR GAMMA; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 27944490844     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi172     Document Type: Article

References (20)

1. Paul LC. Chronic allograft nephropathy: An update. Kidney Int 1999; 56: 783-793
2. Colvin RB. Chronic allograft nephropathy. N Engl J Med 2003; 349: 2288-2290
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333
4. Kasiske BL, Kalil RS, Lee HS et al. Histopathological findings associated with a chronic, progressive decline in renal allograft function. Kidney Int 1991; 40: 514-524
5. Krieger NR, Becker BN, Heisey DM et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related and living-unrelated grafts. Transplantation 2003; 75: 1677-1682
6. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002; 283: F209-F220
7. Fogo AB. Renal fibrosis: Not just PAI-1 in the sky. J Clin Invest 2003; 112: 326-328
8. Lanhlou A, Peraldi MN, Thervet E et al. Chronic graft dysfunction in renal transplant patients: Potential role of plasminogen activator inhibitor type 1. Transplantation 2002; 73: 1290-1295
9. Paukesakon P, Revelo MP, Marcantoni C, Fogo AB. Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy. Kidney Int 2002; 61: 2142-2148
10. Fogo AB. The role of angiotensin II and plasminogen activator-inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-188
11. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: Implications for renal injury. J Nephrol 2002; 15: 230-235
12. Guan YF, Breyer MD. Peroxisome proliferators-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 2001; 60: 14-30
13. Welch JS, Ricote M, Akiyama TA et al. PPAR-γ and PPARδ negatively regulate specific subsets of lipopolysaccharide and INF-γ target genes in macrophages. Proc Natl Acad Sci 2003; 100: 6712-6717
14. Henson P. Suppression of macrophage inflammatory responses by PPARs. Proc Natl Acad Sci 2003; 100: 6295-6296
15. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 2003; 112: 379-388
16. Roberts AW, Thomas A, Rees A, Evans M: Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: Current evidence and future directions. Curr Opin Lipidol 2003; 14: 567-573
17. Zirlik A, Leugers A, Lohrmann J et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004; 91: 674-682
18. Ma LJ, Marcantoni C, Linton MR et al. Peroxisome proliferators-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001; 59: 1899-1910
19. Kanjanabuch T, Ma LJ, Guan YF et al. Protective effects of peroxisome proliferator-activated receptor-gamma (PPAR-γ) against puromycin aminonucleoside (PAN)-induced podocyte injury and death. J Am Soc Nephrol 2003; 14: 93A
20. Wallace A, Minto M, Erwig LP. Heterogeneity of macrophage activation in anti-Thy-1.1 nephritis. Am J Pathol 2003; 163: 2033-2041